A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2018
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Therapeutic Use
- Acronyms PREVENT
- Sponsors Swedish Orphan Biovitrum
- 24 May 2018 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.
- 24 May 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Dec 2020.
- 04 Apr 2017 Status changed from not yet recruiting to recruiting.